JaLCDOI 10.18926/AMO/48076
フルテキストURL 66_1_7.pdf
著者 Kawauchi, Keiichiro| Watanabe, Masami| Kaku, Haruki| Huang, Peng| Sasaki, Kasumi| Sakaguchi, Masakiyo| Ochiai, Kazuhiko| Huh, Nam-ho| Nasu, Yasutomo| Kumon, Hiromi|
抄録 The preclinical safety and therapeutic efficacy of adenoviral vectors that express the REIC/Dkk-3 tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy. The Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer effects in vitro and in vivo, and we herein report the results of two in vivo studies. First, intra-tumor Ad-hREIC administration was examined for toxicity and therapeutic effects in a subcutaneous tumor model using the PC3 prostate cancer cell line. Second, intra-prostatic Ad-mREIC administration was tested for toxicity in normal mice. The whole-body and spleen weights, hematological and serum chemistry parameters, and histological evaluation of tissues from throughout the body were analyzed. Both experiments indicated that there was no significant difference in the examined parameters between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group. In the in vitro analysis using PC3 cells, a significant apoptotic effect was observed after Ad-hREIC treatment. Confirming this observation, the robust anti-tumor efficacy of Ad-hREIC was demonstrated in the in vivo subcutaneous prostate cancer model. Based on the results of these preclinical experiments, we consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clinical treatment of prostate cancer.
キーワード REIC Dickkopf-3 gene therapy prostate cancer preclinical study
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2012-02
66巻
1号
出版者 Okayama University Medical School
開始ページ 7
終了ページ 16
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22358134
Web of Science KeyUT 000300800700002
著者 Ochiai, Kazuhiko| Watanabe, Masami| Ueki, Hideo| Huang, Peng| Fujii, Yasuyuki| Nasu, Yasutomo| Noguchi, Hirofumi| Hirata, Takeshi| Sakaguchi, Masakiyo| Huh, Nam-ho| Kashiwakura, Yuji| Kaku, Haruki| Kumon, Hiromi|
発行日 2011-08-26
出版物タイトル Biochemical and Biophysical Research Communications
412巻
2号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/31719
フルテキストURL fulltext.pdf
著者 Kondo, Asami| Sakaguchi, Masakiyo| Makino, Eiichi| Namba, Masayoshi| Okada, Shigeru| Huh, Nam-ho|
抄録

Using 2-dimensional gel electrophoresis, we previously demonstrated that the S100C protein remarkably decreased after immortalization of normal human fibroblasts, and that this protein caused growth inhibition of human tumor cells when forcibly expressed in these cells, suggesting that S100C plays a significant role in tumor suppression. The present study was carried out to determine what type of human tissues express S100C protein, and, subsequently, whether the S100C content in these tissues changes after normal cells have been transformed into cancer cells. We found that ductal cells in various tissues were positively stained with the S100C protein. In comparison, epithelial cells in digestive organs such as the stomach, small intestine, and colon were not stained as strongly. When 14 pairs of human normal and cancerous tissues were stained with the antibody, decreases in the staining levels of S100C were observed in 6 kinds of cancerous tissues--from the bronchus, mammary duct, renal tubule, prostate, uterus, and testis--in comparison with staining in their normal counterparts. These results suggest that S100C is a new tumor marker protein, the expression of which significantly decreases after malignant transformation of human tissues.

キーワード S100C-antibody human tissues immunostaining
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 2002-02
56巻
1号
出版者 Okayama University Medical School
開始ページ 31
終了ページ 34
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
論文のバージョン publisher
査読 有り
PubMed ID 11873942
Web of Science KeyUT 000174031300006
JaLCDOI 10.18926/AMO/30945
フルテキストURL fulltext.pdf
著者 Kobayashi, Tomoko| Sakaguchi, Masakiyo| Tanimoto, Ryuta| Abarzua, Fernando| Takaishi, Mikiro| Kaku, Haruki| Kataoka, Ken| Saika, Takashi| Nasu, Yasutomo| Miyazaki, Masahiro| Kumon, Hiromi| Huh, Nam-ho|
抄録

We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-REIC) is effective against various human cancers, including those of prostate, testis and breast origins. The aim of the present study was to examine the sensitivity of bladder cancers to Ad-REIC and to clarify the molecular mechanisms that determine sensitivity/resistance. We found that 2 human bladder cancer cell lines, T24 and J82, are resistant to Ad-REIC. In T24 and J82 cells, the ER stress response and activation of JNK were observed in a manner similar to that in the sensitive PC3 cells. Translocation of Bax to mitochondria occurred in PC3 cells but not in T24 and J82 cells. Bcl-2 was remarkably overexpressed in T24 and J82 compared with the expression levels in sensitive cell lines. Treatment of T24 and J82 cells with a Bcl-2 inhibitor sensitized the cells to Ad-REIC-induced apoptosis. The results indicate that some human bladder cancers are resistant to apoptosis induced by overexpression of REIC/Dkk-3, which is at least in part due to up-regulation of Bcl-2. These results provide a basis for possible use of Bcl-2 as a marker of sensitive cancers and to try to sensitize resistant cancers to Ad-REIC by down-regulation of Bcl-2.

キーワード REIC/Dkk-3 bladder cancer apoptosis Bcl-2
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2008-12
62巻
6号
出版者 Okayama University Medical School
開始ページ 393
終了ページ 401
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
論文のバージョン publisher
査読 有り
Web of Science KeyUT 000262025000006
著者 阪口 政清|
発行日 2001-03-25
出版物タイトル
資料タイプ 学位論文